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Abstract Intra-nasal glucocorticoids are the most effec-
tive drugs available for rhinosinusitis and nasal polyposis
treatment. Their effectiveness depends on many factors and
not all of them have been well recognized so far. The
authors present the basic information on molecular mech-
anisms of glucocorticoid action, direct and indirect effects
of glucocorticoids on transcription of genes encoding
inﬂammatory mediators. They focus on recently proved
nongenomic mechanisms which appear quickly, from
several seconds to minutes after glucocorticoid adminis-
tration and discuss clinical implications resulting from this
knowledge. Discovery of nongenomic glucocorticoid
actions allows for better use of these drugs in clinical
practice.
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Introduction
Rhinosinusitis and nasal polyposis are inﬂammatory dis-
eases of nasal and sinuses mucosa leading to limited nose
patency, excessive secretion, anosmia, headaches, and con-
siderable deterioration of quality of life [1–4]. They coexist
or become risk factors for development of other diseases,
includingasthma.Appropriateandearlytreatmentcanbring
notable beneﬁts to patients. In rhinosinusitis and nasal pol-
yposis treatment, intra-nasal glucocorticoids (inGC) are the
most effective drugs available. Intra-nasal glucocorticoids
are recommended not only for allergic rhinitis (AR), but can
be useful in the treatment of some forms of nonallergic rhi-
nitis (NR) [5]. These comprise the ﬁrst-line treatment for
rhinosinusitis [3]. The knowledge of mechanisms of gluco-
corticoids (GC) action helps in their application in appro-
priate clinical situations as using GC is not effective to the
same extent in all patients. However, even though we have
been using glucocorticoids for over 60 years, their exact
mechanism of action is still under discussion. Recently, GC
nongenomic actions are considered which can play an
important roleforthe inhaled (intranasalandintrabronchial)
treatment. This fact was emphasized by the document
‘‘AllergicRhinitisanditsImpactonAsthma(ARIA)’’listing
nongenomic effects as one of the three desirable pharma-
cological properties of inGC [6]. However, the clinical sig-
niﬁcance of nongenomic mechanisms of GC effects is still
not well understood and the reports considering upper air-
ways diseases are scarce.
Glucocorticoid receptor
On the cell level each GC functions through the same
receptor mechanism. The glucocorticoid receptor (GCR)
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mone or a drug (called ligand) mainly by changing gene
expression regulation. GCR is present in all tissues except
anuclear cells. Human airways are characterized by
exceptionally high levels of GCR expression. Within the
nose, the presence of GCR is found in all cells, by the
greatest number in epithelial cells, in submucous glands
and in leucocytes [7].
Glucocorticoid receptor heterogenity
The GCR gene is localized on the ﬁfth chromosome and is
composed of nine exons. As a result of alternative splicing
of GCR primary transcript (mRNA), four variants, called
isoforms, may be produced. The only active isoform is
GCRa, while GCRb, GCRd, and GCRc retain only some
features of full-activity spectrum. GCRb is shorter by 35
amino acids and differs by sequence of other 15 amino
acids from the classic GCRa receptor. The differences
relate to GC binding domain, therefore a total lack of
ability to bind ligand has been reported for this receptor
variant. But yet, it can bind DNA, thus it blocks competi-
tively GCRa access to DNA, not being able to activate gene
expression. Moreover, GCRb can bind directly to the active
GCRa monomer creating nonactive heterodimer. This
additionally inhibits GCRa activity. Additionally, the
half-time period of the GCRb variant is two times longer
than that of GCRa. Therefore, GCRb, holding an antagonist
role, can inhibit signaling pathways of active GCRa and can
cause a secondary resistance to GC. It was shown that pro-
inﬂammatory cytokines (IL-1 IL-2, IL-4, IL-13 and TNFa),
whose participation in polyps and rhinitis pathogenesis is
well substantiated, activate mechanisms of alternative
splicing of mRNA [8–10]. Therefore, inﬂammatory
processes can increase GCRb expression. With the pro-
tracting inﬂammation, ﬁnal GCRb density increases,
therefore GC sensitivity can get decreased. In nasal polyps,
which are not treated by GC, signiﬁcantly higher GCRb
expression occurs in comparison with the unchanged
mucosa [11]. Application of inGC and systemic GC for
2 weeks in those patients, not having any inﬂuence on
GCRb, signiﬁcantly increases GCRa expression in com-
parison with the level shown before treatment and with the
group which did not get GC. A beneﬁcial consequence for a
patient is an increase of GCRa to GCRb ratio. This might be
the way how the high GC doses are able to break the
resistance/decreased sensitivity to GC, which can be a
mechanism of so called medical polypectomy [3]. This
could be the reason why GC with their strong anti-inﬂam-
matory properties are so far the only group of drugs which
can effectively cause a reduction in the size and symptoms
of polyps and prevent their recurrence after surgeries [3, 4].
There is evidence of a dose–response in this effect [12].
Moreover, a delay in decision on GC treatment may cause
failure of nasal polyposis treatment.
Biologic importance of GCRd and GCRc is still being
investigated. Studies suggest that there are many other
more or less active forms of GCR and their expression
depends on a type of stimulus and tissue [13]. Final
explanation of post-transcriptional gene modiﬁcations
(variants of alternative GCR splicing) as reasons for dif-
ferences in GC sensitivity requires further study. However,
it seems that the effectiveness of GC treatment is inﬂu-
enced by keeping appropriate proportions between iso-
forms rather than by their absolute level.
Intracellular localization of glucocorticoid receptor
The unusually wide range of GC actions can be explained
by GCR presence in three cell compartments: nucleus,
cytoplasm, and plasma membrane (Fig. 1).
Initially, it was thought that the primary localization of
GCR was cytoplasm (cGCR) which moves to the nucleus
only after binding the ligand. Now it is clear that the GCR
stays in the nucleus (nGCR). nGCR occurs only in the form
of dimer and after activation by the ligand interacts with
DNA to intensify or inhibit gene transcription, directly. In
cytoplasm GCR occurs as monomer, which enables the
protein–protein interaction with other extranuclear regula-
tory proteins and, indirectly, gene transcription modiﬁca-
tion. Both types of action, cytoplasmatic and nuclear, are
deﬁned as genomic ones since they take place through
regulation of gene activity. The possibility of GCR
occurrence in cell membrane has been postulated for a long
time, but its presence in this cell area was conﬁrmed only
in 2004 thanks to immunoﬂuorescence staining with the
Fig. 1 Intracellular localization of glucocorticoid receptor (plasma
membrane, cytoplasm and nucleus) and nongenomic and genomic
mechanism of glucocorticoids actions
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123use of liposomes [14]. Membrane GC receptors (mGCR)
initiate rapid changes in activity of various signal pathways
when activated by GC. These mechanisms are called
nongenomic ones.
Genomic mechanisms of glucocorticoid action
The classical model of GC action includes their inﬂuence
(direct or indirect) on gene transcription and translation, for
many speciﬁc genes encoding inﬂammatory mediators
(Fig. 1). Genomic effects appear not earlier than after tens
of minutes. The ARIA directives for inGC deﬁne this
time as 7–8 h following administration [6]. The time
for reaching maximal effectiveness can be even up to
2 weeks [6].
In the cytoplasm, the nonactive receptor is present in a
complex with chaperones. The GC-activated GCR under-
goesaninitialconformationchange,resultingindissociation
of the chaperone–GCR complex. In this way the GC–GCR
complexisactivatedandcantranslocatetothenucleuswhere
it dimerizes. Only as a homodimer it can bind to the DNA
regulatory sequences, called GC response elements (GRE)
and found in the promoter regions of glucocorticoid-regu-
lated genes. If the GC–GCR complex binding leads to gene
activation, the GRE sequence is termed as ‘‘positive’’ GRE.
GCcausesactivationofthegeneslistedinTable 1.Negative
GRE is also described where GC–GCR leads to gene
suppression (direct repression). So far, the presence of
negative GRE in the promotor region was proved only for a
few genes (Table 1).
The GC–GCR and DNA binding provides a signal for
coactivator CBP proteins (CREB binding protein), pCAF
(p300-CBP associated factor) and SRC-1 (steroid receptor
coactivator-1). Coactivator proteins with inner histone
acetyltransferase (HAT) activity loosen the DNA strand
and facilitate RNA polymerase II and TATA-box binding
protein (TBP) actions, which conditions initiation of tran-
scription [15].
Many genes may be inﬂuenced by GC without direct
interaction with DNA (Table 1). It happens through bind-
ing of factors important for inﬂammatory process devel-
opment, often coactivators or corepressors of other genes’
transcription. The process of gene transcription inhibition
without DNA binding is called indirect transrepression.
The most important GC anti-inﬂammatory effects, crucial
for patients with inﬂammatory diseases, take place in this
mechanism [15, 16]. Within the cytoplasm, the active GC–
GCR complex functions as a monomer and takes part in
interactions with many proteins (protein–protein interac-
tion), among them signaling pathways kinases, transcrip-
tion factors, coactivator proteins, preventing their
interactions within the nucleus area. An example is the
inhibition of transcription factors, such as activator protein
(AP-1) and nuclear factor kappa B (NFjB) and signal
transducers and activators of transcription (STAT) [15].
These transcription factors activate the expression of genes
responsible for inﬂammatory processes, antiapoptotic
genes and genes regulating cell proliferation. Interaction of
protein–protein type with GC–GCR complex wipes out
their regulatory effects on gene expression. The GC–GCR
complex in the cytoplasm area can also bind proteins with
HAT activity (i.e., pCAF, CBP, SRC-1). In this manner the
GC inhibits HAT activity directly and recruits HDAC2,
which modiﬁes the histone structure into more condensed,
limiting the access of transcription factors to DNA (‘‘gene
silencing’’) [15, 17].
Microarray studies of nasal polyps conﬁrmed the wide
range of GC genomic actions. Benson et al. [18] reported
that ﬂuticasone changed expression of 203 genes, among
them 139 of known function, genes associated with
inﬂammation constituting the largest group. It appeared
that in nasal polyps inGC not only downregulated proin-
ﬂammatory genes but also upregulated anti-inﬂammatory
genes. The most highly expressed gene was that producing
uteroglobulin. Uteroglobulin is a protein secreted in the
lungs by Clara cells, which inhibit leukocyte chemotaxy,
A2 phospholipase activity and proinﬂammatory cytokines
activity. Its expression in nasal polyps is considerably
decreased (11 times) in comparison with the level of
expression observed in healthy mucous membranes [18].
Therefore, a signiﬁcant increase of uteroglobulin gene
expression under the inﬂuence of inGC treatment can be a
vital element of their activity in nasal polyps.
Nongenomic mechanism of glucocorticoid actions
For a long time GC effects on gene transcription were
considered as the only mechanism of its action. However,
the genomic mode of action implies delayed response to
GC, as start of speciﬁc regulatory protein synthesis occurs
at 20–30 min to hours after cell exposition to GC, and only
then gradually their activity develops [19]. This was not
always compatible with clinical observations. Clinical
practice and in vitro and in vivo studies showed some
examples of GC therapy effects taking place fast, within
minutes or even seconds, in the time excluding protein
production de novo [20–25].
Experimental models enable to diversify genomic and
nongenomic mechanisms of GC effects. If the activity
under study can be observed after transcription (actino-
mycin D) or translation (cycloheximide) inhibitors
administration or in the material of anuclear cells, the
nongenomic mode of action is to be implied. The time of
biological effects alone does not distinguish precisely both
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123mechanisms because nongenomic ones occurring after
longer time cannot be excluded.
GC receptor localized in cell membrane, more rarely in
cytoplasm, is responsible for nongenomic GC actions.
Nontranscriptive signal can be mediated also without
receptor involvement. It was shown that some rapid GC
actions are not inhibited by their receptor antagonists. In
this mechanism GC activate secondary messengers (cal-
cium ions Ca
2?, inositol trisphosphate IP3, diacylglycerol
DAG and cyclic nucleotides: cAMP and cGMP). Increase
of activity of a secondary messenger induces kinase (or
several kinases) activity dependent on it and in conse-
quence changes course of cellular processes. Mitogen-
activated protein kinases (MAPK), including mainly
protein ERK1/2 and p38 play a substantial role in GC
nontranscriptional signals. Other kinases: protein kinase A
(PKA) and C (PKC), tyrosine kinase (i.e. Src), lipid kinases
(i.e. inositol trisphosphate kinase––PI3K) and signaling
pathways related to protein G and ion channels are also
involved [17, 26].
Nongenomic GC effects mediated via membrane
glucocorticoid receptors
Some nongenomic GC effects are mediated via membrane
GCR (mGCR). Activated mCCR can stimulate synthesis of
secondary messengers and enter into interactions with ion
channels protein. There is evidence that rapid GC actions
take place through interactions with membrane receptor
coupled with G protein (GPCR, G protein coupled
receptors). GC, directly or via mGCR, can be bound to Gs
protein subunit a activating adenyl cyclase. This contrib-
utes to activation of Gs-cAMP-PKA signaling pathway.
Membrane GCR is also an important regulator of T cell
receptor (TCR) signaling [26].
Nongenomic GC effects mediated via cytoplasmic
glucocorticoid receptors
In nongenomic action GCR localized in cytoplasm (cGCR)
may be involved. Croxtall et al. [23] showed rapid inhi-
bition of arachidonic acid release by dexamethasone which
was dependent on the receptor since the reaction did not
occur after cell exposition to receptor inhibitor (RU 486).
In contrast, its course was not inﬂuenced by transcription
inhibitor (acitinomycin D). It appeared that binding dexa-
methasone to GCR caused not only receptor dissociation
from Hsp90 chaperones but also a release of Src tyrosine
kinases from the complex with Hsp90, which according to
the authors inhibited release of arachidonic acid by rapid
signaling pathway without any involvement on gene
transcription.
Nongenomic GC effects may occur without receptor
involvement
GC-mediated signaling without GCR involvement has been
poorly understood. GC, as highly lipophilic compounds,
diffuse easily in lipid cell membranes interfering with their
Table 1 Molecular mechanisms of glucocorticoids action
Nongenomic
Effect on secondary messenger systems
Regulation of membrane ion channels
Regulation of T cell receptor (TCR) signaling
Effect on G protein signaling
Stimulation the release of Src kinase
Genomic
Gene activation
Annexin-1 (lipocortin-1), b2-adrenergic receptor, inhibitor of NFjB (I-jBa), secretory leukoprotease
inhibitor (SLPI), Clara cell protein 10 (CC10), IL-1 receptor antagonist, IL-10, mitogen-activated kinase
phosphatase-1 (MKP-1), glucocorticoid-induced leucine zipper protein (GILZ)
Gene repression
Direct
Proopiomelanocortin, corticotrophin releasing factor, osteocalcin, keratins
Indirect
Cytokines: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-13, IL-16, IL-17, IL-18, TNFa, GM-CSF;
Chemokines: RANTES, MIP-1a, eotaxin
Enzymes: inducible nitric oxide synthase, inducible cyclooxygenase
Receptors: bradykinin b2-receptor, tachykinin NK1-receptor, NK-2 receptor
250 Eur Arch Otorhinolaryngol (2011) 268:247–253
123molecules and inﬂuencing their physicochemical proper-
ties. This nonspeciﬁc GC activity is related mainly to
membrane ion (calcium, sodium, potassium, chloride)
channels regulation and its result is preserving ﬂuidity and
continuity of cell membrane. It was proved that GC
megadoses, in a receptor independent mechanism, can
inhibit neutrophil degranulation and superoxide anion
production within 5 min [24, 25]. Next, dexamethasone,
reversing the process of intracellular calcium ion accu-
mulation, can decrease secretion of chloride ions through
bronchial epithelium [27]. The above-mentioned activities
can inﬂuence the development of nasal polyps. Berstein
et al. [28] believe that intensiﬁed transepithelial ion
transport, induced by inﬂammatory condition, is a basic
pathologic change in nasal polyps. It makes water relocate
into interstitial space, inducing edema and the formation of
nasal polyps. According to the authors of this hypothesis,
excessive Na
? ion absorption and increased Cl
- perme-
ability are crucial for this effect [28].
Conditions of nongenomic GC effects activation
Many aspects of nongenomic GC actions require further
studies. The most important question is conditions of
nongenomic signaling pathways activation. So far we know
that nongenomic mechanisms of GC actions appear espe-
cially with higher doses and as a consequence, with higher
local ligand concentration in cell. In a randomized, pla-
cebo-controlled, double-blind study it was shown that nasal
itching was markedly reduced within 10 min after admin-
istration of the study drug following either a single high
dose of systemic GC, betamethasone (60 mg) or methyl-
prednisolone (400 mg) given intravenously [29]. Accord-
ing to Buttgereit et al. [30] genomic mechanisms can be
revealed with the concentration above 10
-12 M, while
nongenomic with the concentration of at least 10
-9 M. In
contrast, other authors show that preserving ﬂuidity of cell
membrane and integration of proteins forming cell mem-
brane (i.e., ion channel proteins, transporting and recep-
tors) require GC concentration above 10
-4 M[ 31].
Nongenomic GC effects can also be dependent on GC
afﬁnity to its receptor [23]. In this aspect it should be
considered that inGC administration ensures high local
concentration of the drug (despite low doses applied). The
inGC preparations were characterized by considerably
higher afﬁnity to its receptor and local potency in com-
parison to their equivalents administered systemically [32,
33]. Such clinical situation can be favorable for revealing
nongenomic mechanisms of inGC actions.
The conditions of all inGC effects are appropriate site of
their deposition. One large challenge regarding inGC is
insufﬁcient distribution in the nose and paranasal sinuses to
mucosal obstruction, especially in cases with nasal polyps.
That’s why in some cases a good effect with combined
treatment using inGC and oral treatment (for short term) is
observed [3].
GC effects on the airway vasculature
The nose has a rich supply of blood vessels. During
inﬂammation, hyperemia, increased blood ﬂow, micro-
vascular permeability, and edema formation occur quite
quickly. Some authors claim that it is just large quantities
of extracellular ﬂuid that contribute to polyps’ develop-
ment (Bateman’s hypothesis) [34]. Moreover, a signiﬁcant
increase of vascular endothelial growth factor (VEGF)
expression was shown [35]. This cytokine is a vital angi-
ogenesis stimulator and causes an increase of vessel per-
meability and dilatation stimulating nitrogen oxide
synthesis through endothelium. VEGF also stimulates
proteolytic enzymes and expression of receptors important
for cell migration and epithelial cells proliferation. The
increase in VEGF concentration in nasal lavage from
patients with polyposis compared with control subjects is
so high (sevenfold higher) that VEGF was acknowledged
to be a novel biomarker for chronic rhinosinusitis with
hyperplastic sinonasal polyposis. It was also shown that
epithelial infection with rhinovirus speciﬁcally stimulated
VEGF mRNA expression and VEGF release in normal
subjects or atopic patients [36].
For the reasons presented above, GC inﬂuence on vas-
culature is an important element of their effectiveness. It
was shown that GC exerts rapid, delayed and long-term
effects on the airway vasculature [22]. Long-term effects
are above all a consequence of GC anti-inﬂammatory
action, and as a result they suppress increased microvas-
cular permeability and oedema formation. GC inhibition of
VEGF expression is also signiﬁcant due to inhibition on the
molecular level of oedema formation. Glucocorticoids (as
proved by GC given intrabronchially) can also decrease
considerably blood ﬂow in mucous membrane vessels. This
effect appears quickly, in less than 5 min, which suggests
nongenomic type of action [22]. It is thought that GC, in
this activity, inhibit extraneuronal uptake of norepinephrine
within a1-adrenoreceptor in vascular smooth muscle cells
[22]. Clinical symptom of this activity is decrease of
hyperaemia in the site of inﬂammation as a result of sig-
niﬁcant decrease of blood ﬂow in mucous membrane ves-
sels (a1-adrenoreceptor-dependent vasoconstriction of GC).
Local regulation of blood ﬂow and membrane ion
channels, can mediate the antisecretory [20] and decon-
gestant effects of inGC in patients with vasomotor rhinitis
[37, 38], rhinitis medicamentosa [39] and rhinosinusitis
with or without polyps [40].
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123Final remarks
Intra-nasal GCs are the most important drugs in upper
airways diseases. Proving not only slow genomic GC
action but also rapid nongenomic mechanisms justiﬁes
wider indications for inGC administration in upper airway
diseases with mechanism other than classic chronic
inﬂammation such as medicamentosa and vasomotor rhi-
nitis. The presented mechanisms of GC actions indicate
that inGCs are effective not only in allergic rhinitis but
should also be drugs of ﬁrst choice in cases coexisting with
nonallergic rhinitis (44–87% cases) [5, 41]. The use of
inGC both as monotherapy and adjunctive therapy for
acute rhinosinusitis [4] is also supported by the molecular
mechanism of GC action. Intra-nasal GCs should be
applied regularly for a longer period, but in some cases
their occasional use is acceptable (also on an as-needed
basis) [5] and this recommendation is based on nonge-
nomic rapid GC effects. InGC should also be drugs of the
ﬁrst choice in the treatment of nasal and sinus polyps
because they give a chance of eliminating or decreasing
their size. They should be applied as primary treatment in
prevention of disease recurrence after surgical treatment.
Taking into consideration situations when nongenomic GC
effects get revealed, it should be remembered that in some
cases the drug doses should be deﬁnitely higher than those
recommended conventionally. The more that, there are
inGC preparations available of high afﬁnity to GCR (which
can provide higher chances for disclosing nongenomic
actions) and low systemic bioavailability (which provides
safety). The current systematic reviews and meta-analyses
emphasize their safety as ﬂuticasone propionate and furo-
ate and mometasone furoate systemic bioavailability is
\1% [42]. Should be glad that the role of inGC is more
often recognized as an appropriate and effective treatment
option [43].
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